Ilaria Minato

Dr. Ilaria Minato

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2020 in Nanomaterials
Verified
Journal Article
Open access
PDF file
RRRoberta Ruotolo
Roberta Ruotolo
GGGiuseppe De Giorgio
Giuseppe De Giorgio
IMIlaria Minato
Ilaria Minato
MBMassimiliano G. Bianchi
Massimiliano G. Bianchi
OBOvidio Bussolati
Ovidio Bussolati
Nelson MarmiroliNelson Marmiroli
Nelson Marmiroli
Over the last decades, cerium oxide nanoparticles (CeO2 NPs) have gained great interest due to their potential applications, mainly in the fields of agriculture and biomedicine. Promising effects of CeO2 NPs are recently shown in some neurodegenerative diseases, but the mechanism of action of these NPs in Parkinson’s disease (PD) remains to be investigated. This issue is addressed in the present study by using a yeast model based on the heterologous expression of the human α-synuclein (α-syn), the major component of Lewy bodies, which represent a neuropathological hallmark of PD. We observed that CeO2 NPs strongly reduce α-syn-induced toxicity in a dose-dependent manner. This effect is associated with the inhibition of cytoplasmic α-syn foci accumulation, resulting in plasma membrane localization of α-syn after NP treatment. Moreover, CeO2 NPs counteract the α-syn-induced mitochondrial dysfunction and decrease reactive oxygen species (ROS) production in yeast cells. In vitro binding assay using cell lysates showed that α-syn is adsorbed on the surface of CeO2 NPs, suggesting that these NPs may act as a strong inhibitor of α-syn toxicity not only acting as a radical scavenger, but through a direct interaction with α-syn in vivo.

8 January 2020 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
RRRoberta Ruotolo
Roberta Ruotolo
IMIlaria Minato
Ilaria Minato
PVPietro La Vitola
Pietro La Vitola
LALuisa Artioli
Luisa Artioli
CCClaudio Curti
Claudio Curti
SOSimone Ottonello
Simone Ottonello

21 April 2025 in Molecular Nutrition & Food Research
Verified
Journal Article
Open access
IMIlaria Minato
Ilaria Minato
Pedro MenaPedro Mena
Pedro Mena
Luigi RicciardielloLuigi Ricciardiello
Luigi Ricciardiello
ESEleonora Scaioli
Eleonora Scaioli
ABAndrea Belluzzi
Andrea Belluzzi
Francesca DanesiFrancesca Danesi
Francesca Danesi
This study aimed at investigating the effects of pomegranate juice (POMJ) consumption on inflammatory biomarkers and gene expression in patients with inflammatory bowel disease (IBD) in clinical remission. In this randomized, placebo‐controlled trial, 16 subjects with IBD in remission consumed POMJ or placebo for 12 weeks. POMJ consumption significantly reduced fecal calprotectin (FC) and plasma endotoxin levels. Transcriptomic analysis of peripheral blood mononuclear cells revealed upregulation of genes involved in mucosal immunity, including aryl hydrocarbon receptor ( AHR ), neutrophil cytosolic factor 4 ( NCF4 ), and nuclear factor, interleukin 3 regulated ( NFIL3 ). Urolithin metabotypes were predominantly of the B type, associated with intestinal dysbiosis. No significant changes were observed in serum inflammatory markers or colonic mucosal cytokine expression. POMJ consumption reduced markers of intestinal inflammation and modulated gene expression related to mucosal immunity and barrier function in patients with IBD. These findings suggest the potential of POMJ as a beneficial dietary intervention for maintaining remission in IBD, highlighting the promise of targeted nutritional strategies in managing chronic inflammatory conditions. Further research is needed to elucidate the long‐term clinical implications of these molecular changes. Trial Registration: ClinicalTrials.gov identifier: NCT03000101 .